Updated April 27 at 9:27pm
Biotechnology
39 results total, viewing 1 - 10
Venture capitalists invested $124.1 million in Rhode Island companies in 2014, $42 million more than in 2013, and the largest amount to date, according to the MoneyTree Report by PricewaterhouseCoopers LLP and the National Venture Capital Association. more
Steve Lombardi has been named CEO and president of Nabsys Inc., a life sciences company pioneering semiconductor-based tools for genomic analysis. more
EpiVax Inc. and Novozymes Biopharma entered into a license agreement for the development of treatments for autoimmune diseases, the companies announced on Monday. more
A Japanese biopharmaceutical company has contracted to begin using a protein-screening interface developed by Providence-based EpiVax Inc. more
(Updated, 5:14 p.m.) A Cherrystone Angel Group portfolio business has entered into an acquisition agreement of $140 million with a European buyer specializing in bio-analytical testing and genomic services. more
Dr. Anne S. De Groot, EpiVax CEO and University of Rhode Island professor, has been named one of the most influential people in the vaccine industry by the national vaccine industry organization VaccineNation. more
The co-founder and president of MedMates, Rhode Island’s first health care technology network group, and co-founder and director of an emerging health-tech company, Aspiera Medical, talks about starting a company in Rhode Island and what he expects MedMates to look like down the road. more
A Cherrystone Angel Group portfolio company, Windgap Medical Inc., was awarded nearly $1 million through a Massachusetts Life Sciences Center accelerator loan program. more
Mnemosyne Pharmaceuticals Inc. appointment of Vanessa King as president and CEO. more
IlluminOss Medical has been issued two patents related to its internal bone fixing system, the company announced Tuesday. more
1 | 2 | 3 | 4 Next »